referral to ema, page-50

Resourced, yes money is a factor and will more than likely need to be addressed, especially if this drags out and is forwarded to the EMA. From my understanding most of the costs for preparation for the FDA clinical trial applications have already been incurred, but imo there's still a lot more cost to run the trials etc.

I disagree that they have too much inventory and that every decision was "Bad" by management and the board as you so authoritively put it, as if you know how to run a Biotech company and as if you know or knew what was being said between BSI - Management - Board members. Why make such statements, it's childish to say the least!!